Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $25.00 price objective on the stock. HC Wainwright‘s price objective points to a potential upside of 296.83% from the company’s current price.
Several other equities research analysts have also issued reports on the stock. Wall Street Zen raised shares of Cartesian Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cartesian Therapeutics in a research note on Wednesday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, September 29th. Wedbush reiterated an “outperform” rating and set a $38.00 price target on shares of Cartesian Therapeutics in a report on Tuesday, August 18th. Finally, Zacks Research upgraded shares of Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.60.
Read Our Latest Stock Analysis on RNAC
Cartesian Therapeutics Trading Up 2.9%
Cartesian Therapeutics stock opened at $6.30 on Thursday. Cartesian Therapeutics has a 12-month low of $5.60 and a 12-month high of $11.00. The business’s 50-day moving average price is $6.97 and its two-hundred day moving average price is $7.61.
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.63. As a group, equities research analysts forecast that Cartesian Therapeutics will post -2.19 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Sei Investments Co. bought a new position in Cartesian Therapeutics in the 1st quarter valued at approximately $78,000. Empowered Funds LLC bought a new stake in Cartesian Therapeutics during the 3rd quarter worth approximately $180,000. Bank of New York Mellon Corp acquired a new position in Cartesian Therapeutics in the 2nd quarter valued at approximately $332,000. Renaissance Technologies LLC increased its position in Cartesian Therapeutics by 63.7% in the 1st quarter. Renaissance Technologies LLC now owns 67,300 shares of the company’s stock valued at $414,000 after acquiring an additional 26,200 shares during the period. Finally, Privium Fund Management B.V. increased its position in Cartesian Therapeutics by 2.2% in the 3rd quarter. Privium Fund Management B.V. now owns 155,000 shares of the company’s stock valued at $1,118,000 after acquiring an additional 3,325 shares during the period. Institutional investors and hedge funds own 86.95% of the company’s stock.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company developing RNA-engineered cell therapies for autoimmune diseases and cancer. Its platform uses messenger RNA to program immune cells, including T cells, to recognize and target disease-associated cells. The company’s lead program, Descartes-08, is an autologous CAR T-cell therapy designed to target BCMA and being studied for generalized myasthenia gravis. Unlike gene-modified cell therapies that rely on permanent genetic changes, Cartesian’s approach uses RNA to produce temporary cell modifications.
Recommended Stories
- Five stocks we like better than Cartesian Therapeutics
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
